Repurposing Ponatinib as a Potent Agent against KIT Mutant Melanomas.
Ontology highlight
ABSTRACT: Rationale: Mutations in KIT, a major cancer driver gene, are now considered as important drug targets for the treatment of melanomas arising from mucosal and acral tissues and from chronically sun-damaged sites. At present, imatinib is the only targeted drug for KIT-mutation-bearing melanomas that is recommended by the National Comprehensive Cancer Network (NCCN) Clinical Practice guidelines. Patients with KIT mutations, however, are either insensitive or rapidly progress to imatinib insensitivity, which restricts its clinical use. Thus, effective inhibitors of KIT-mutation-bearing melanomas are urgently needed. Methods: A cohort of patient-derived tumor xenograft (PDX) models and corresponding PDX-derived cells (PDCs) from patients with melanomas
SUBMITTER: Han Y
PROVIDER: S-EPMC6485277 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA